Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $30.56.

A number of equities research analysts have recently commented on KROS shares. HC Wainwright cut their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. Truist Financial cut their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th.

Keros Therapeutics Price Performance

KROS stock traded up $0.41 during midday trading on Friday, hitting $14.32. The stock had a trading volume of 599,913 shares, compared to its average volume of 866,049. The firm has a market cap of $581.68 million, a price-to-earnings ratio of -79.56 and a beta of 1.26. The business has a 50-day moving average of $13.97 and a two-hundred day moving average of $12.82. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. During the same period in the prior year, the firm earned ($1.21) earnings per share. Research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new position in Keros Therapeutics in the first quarter worth about $25,000. CWM LLC boosted its position in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after purchasing an additional 2,641 shares during the last quarter. AlphaQuest LLC boosted its position in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Keros Therapeutics in the fourth quarter worth about $90,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.